Skip to main content

Targeted Herpesvirus-derived Oncolytic Vectors for Liver cancer European Network

Objective

The overall objective of THOVLEN is to develop safe and efficient herpes simplex virus type 1 (HSV-1)-derived oncolytic vectors, designed to strictly target and eradicate human hepatocellular carcinomas (HCC), the most common liver cancer of adults. HSV-1 is certainly one of the most promising viral platforms for the development of improved oncolytic vectors, as anticipated by the unique biological properties of this virus and confirmed by the encouraging results coming from clinical trials in gliomas. However, the first generations of oncolytic HSV-1 vectors have also shown limitations regarding efficacy and safety. New generations of innovative HSV-1 vectors with improved potency and safety are required before the oncolytic strategy using HSV-1 becom es a standard therapeutic reality against cancer, and this is the goal of THOVLEN. One of the most important innovative contributions of our project concerns the overall approach towards the improvement of HSV-1-based oncolytic viruses. Instead of focusi ng on the development of vectors carrying deletions in particular virus genes, we will engineer competent, but replication-restricted, HSV-1 vectors, strictly targeted to HCC. These vectors will combine multiple HCC-targeting approaches, both at the leve l of entry and at the level of gene expression and replication, and will be able to multiply and spread only in HCC, while displaying no virulence in normal healthy tissues. Additionally, an important innovation is related to the ability of the HSV-1 vec tors to permit a sophisticated and flexible combined approach against HCC. That is, in addition to optimizing the oncolytic properties of HSV-1 vectors, THOVLEN will exploit the very large transgenic capability of HSV-1 to generate vectors that will sim ultaneously display multiple and multimodal anti-tumour activities acting either locally or systemically, including combined expression of anti-angiogenic, immune-modulatory, and oncolytic pr

Call for proposal

FP6-2004-LIFESCIHEALTH-5
See other projects for this call

Coordinator

UNIVERSITÉ CLAUDE BERNARD LYON 1
Address
43 Boulevard Du 11 Novembre 1918
Villeurbanne
France

See on map

Participants (7)

FUNDACION PARA LA INVESTIGACION MEDICA APLICADA
Spain
Address
Avda Pio Xii, 55
Pamplona

See on map

GENOPOIETIC
France
Address
1390 Rue Centrale
Miribel

See on map

Links
INSTITUT PASTEUR HELLENIQUE
Greece
Address
127 Vassilissis Sofias Ave
Athens

See on map

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany
Address
Geschwister-scholl-platz 1
Muenchen

See on map

LYON 1 INGENIERIE
France
Address
43 Bd Du 11 Novembre 1918 - L'atrium
Villeurbanne

See on map

NUCLEALP
France
Address
Les Rey
Cusy

See on map

Links
UNIVERSITA DEGLI STUDI DI FERRARA
Italy
Address
Via Savonarola N° 9
Ferrara

See on map